StockWatch
·
Q2 FY-2027 RESULTS · AKUMS

Akums Q2 FY27: Consol PAT up 168% YoY to ₹114.6 Cr, revenue +32%, margin in guided band

PAT +168.29% YoY · revenue +31.93% · margins expanding

Q2 FY27 resultsAKUMSAkums Drugs and Pharmaceuticals Ltd02 Nov 2026 · 3 min read
Revenue

₹1,342.39 Cr

+31.93% YoY

PAT (consolidated)

₹114.57 Cr

+168.29% YoY

Net margin

8.35%

+4.3pp YoY

EPS

₹7.37

Akums' consolidated Q2 FY27 (quarter ended 30 September 2026) revenue rose 31.9% YoY to ₹1,342.4 Cr and PAT surged 168.3% YoY to ₹114.6 Cr, with NPM expanding to 8.35% from 4.07% and OPM (EBITDA margin) to 14.51% from 9.28% a year ago — a straightforward YoY growth-cum-margin-expansion quarter, not a one-off: neither this quarter nor the year-ago quarter carried any exceptional item, so the 168% is a clean comparison. Sequentially the picture is milder — revenue +15.1% QoQ and PAT +13.5% QoQ — and OPM actually eased to 14.51% from Q1's 14.97%, so the QoQ print should be read as a continuation of an already-strong base rather than fresh acceleration; NPM similarly ticked down marginally QoQ (8.44%→8.35%).

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹1,342.39 Cr+15.1%+31.9%
Expenses₹1,216.55 Cr+15%+23.6%
PAT₹114.57 Cr+13.46%+168.29%
Net margin8.35%-0.1pp+4.3pp
EPS₹7.37+12.9%+177.1%

The margin story sits mainly in CDMO, the largest segment: external revenue grew 38.6% YoY to ₹1,114.9 Cr and segment result (post-depreciation) more than doubled to ₹259.0 Cr from ₹91.6 Cr, comfortably ahead of management's "high-teens volume growth" guidance from the Q1 FY27 call (value growth here is well above that bar, though volume is not separately disclosed). API, flagged for a monthly-EBITDA-breakeven target by end-FY27, narrowed its segment loss to -₹10.1 Cr from -₹18.4 Cr YoY — directionally on track — but the loss actually widened from Q1's -₹8.1 Cr, so the path isn't linear and bears watching. The reported 14.51% OPM sits inside management's reiterated 14–15% EBITDA margin target, meeting guidance, though it is off Q1's print which the company had flagged as running toward the "upper bracket." No public consensus estimate for this specific quarter turned up in a search of brokerage previews; the only available Street benchmark is a ~₹4,920 Cr FY27 full-year revenue consensus (+12.9%), against which Akums is tracking at ₹2,509 Cr for H1 FY27 — broadly consistent, not confirmable on PAT.

₹
638.17690.3742.43794.55846.68733.1507-3008-2109-1510-0811-02Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹733.15, down 9.9% over the past month of trading.

₹ Cr
042.7785.55128.3264.69Q1 FY26rev ₹1,024 Cr42.7Q2 FY26rev ₹1,018 Cr67.67Q3 FY26rev ₹1,160 Cr81.34Q4 FY26rev ₹1,158 Cr100.98Q1 FY27rev ₹1,167 Cr114.57Q2 FY27rev ₹1,342 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 4 consecutive quarters.

Beyond the headline

What the summary numbers don't show

Standalone (parent-only) PAT grew a much slower 39% YoY to ₹32.6 Cr on revenue +27.7% to ₹395.0 Cr — consolidated's outsized growth is driven by subsidiaries, not the parent

Consolidated basic EPS ₹7.37 vs ₹6.53 (Q1 FY27) and ₹2.66 (Q2 FY26)

What management guided (1 FY-2027 call)
CDMO high-teens volume growth Q2-onwards. Maintain 14–15% EBITDA margin target; bias toward upper bracket given Q1 strength. Zambia ~₹240 Cr in H2 FY27, similar FY28 at higher-teen EBITDA margins. API to reach monthly EBITDA breakeven by end FY27.

— This quarter: met

On corporate developments, the quarter included Pure and Cure Healthcare's ₹56.0 Cr acquisition of Oriflame India's Roorkee and Noida manufacturing facilities, a stated capacity and color-cosmetics/skincare/wellness expansion move that is incremental to this quarter's P&L (deal completed during the quarter). A subsidiary separately received a ₹52.7 Cr NPPA demand notice in October, outside this result's numbers but a monitorable for the segment's liability position. Management's own press release framing — "PAT surges 168% YoY on margin expansion, revenue up 32%" — matches the reported figures without rounding discrepancies; no prior-quarter outlook from the company is contradicted by this print, and the cautiously-optimistic short-term tone from the August concall is borne out by the margin trajectory, even as Zambia's guided ~₹240 Cr H2 FY27 contribution is not yet separately visible in this segment breakout.

  • W1

    API segment path to monthly EBITDA breakeven by end-FY27 — Q2 segment loss of -₹10.1 Cr widened from Q1's -₹8.1 Cr despite narrowing YoY; watch Q3 trajectory

  • W2

    OPM within the 14–15% guided band (14.51% this quarter, down from Q1's 14.97% 'upper bracket' print) — watch whether it holds or slips further toward the lower end in H2

  • W3

    Zambia ramp toward management's guided ~₹240 Cr H2 FY27 revenue at higher-teen EBITDA margins — not yet separately visible in this quarter's segment disclosure

Clean digital filing, both schedules fully legible; no exceptional items in Q2 FY27, Q1 FY27 or Q2 FY26 quarters (FY26 full-year had a ₹20.0 Cr exceptional item, not in any compared quarter) so no raw-vs-adjusted PAT split needed. Consolidated PAT of ₹114.57 Cr includes ₹1.71 Cr non-controlling interest; owners'-share PAT is ₹112.85 Cr. Standalone PAT grew only ~39% YoY vs consolidated's 168% YoY — the gap is subsidiary-level margin improvement, not the parent. Ongoing IT-department search/seizure tax demand (₹156.0 Cr consolidated, block period FY19-FY25) carries no P&L adjustment per management/legal assessment.

Informational and educational content only. Not investment advice.